These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 35590394)

  • 1. The importance of N6-methyladenosine modification in tumor immunity and immunotherapy.
    Zhang Z; Liu F; Chen W; Liao Z; Zhang W; Zhang B; Liang H; Chu L; Zhang Z
    Exp Hematol Oncol; 2022 May; 11(1):30. PubMed ID: 35590394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of N6-methyladenosine RNA modification in cancer.
    Qu Y; Gao N; Zhang S; Gao L; He B; Wang C; Gong C; Shi Q; Li Z; Yang S; Xiao Y
    MedComm (2020); 2024 Sep; 5(9):e715. PubMed ID: 39252821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy.
    Guo L; Yang H; Zhou C; Shi Y; Huang L; Zhang J
    Front Immunol; 2021; 12():773570. PubMed ID: 34956201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles and therapeutic implications of m6A modification in cancer immunotherapy.
    Pan J; Huang T; Deng Z; Zou C
    Front Immunol; 2023; 14():1132601. PubMed ID: 36960074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma.
    Li H; Hu J; Yu A; Othmane B; Guo T; Liu J; Cheng C; Chen J; Zu X
    Front Oncol; 2021; 11():642159. PubMed ID: 33816290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer.
    Liu J; Wang J; Wu M; Zhang W; Meng L; Wang J; Lv Z; Xia H; Zhang Y; Wang J
    Front Med (Lausanne); 2021; 8():757432. PubMed ID: 35004726
    [No Abstract]   [Full Text] [Related]  

  • 7. Manipulating the tumour immune microenvironment by N6-methyladenosine RNA modification.
    Sun X; Wang H; Pu X; Wu Y; Yuan X; Wang X; Lu H
    Cancer Gene Ther; 2024 Sep; 31(9):1315-1322. PubMed ID: 38834772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research Advances in the Roles of N6-Methyladenosine Modification in Ovarian Cancer.
    Zhang Y; Ling Y; Zhou Y; Shi X; Shen F; Zhou J; Chen Y; Yang F; Gu Y; Wang J
    Cancer Control; 2024; 31():10732748241256819. PubMed ID: 38755968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N6-methyladenosine Regulator-Mediated Immune Genes Identify Breast Cancer Immune Subtypes and Predict Immunotherapy Efficacy.
    Zhang MM; Lin YL; Zeng WF; Li Y; Yang Y; Liu M; Ye YJ; Jiang KW; Wang S; Wang S
    Front Genet; 2021; 12():790888. PubMed ID: 34976022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalk between N6-methyladenosine (m6A) modification and noncoding RNA in tumor microenvironment.
    Wang D; Han Y; Peng L; Huang T; He X; Wang J; Ou C
    Int J Biol Sci; 2023; 19(7):2198-2219. PubMed ID: 37151887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N6-methyladenosine modification participates in neoplastic immunoregulation and tumorigenesis.
    Zhao W; Li J; Ma Q; Cai J; Li A; Wu W; Lv Y; Cai M
    J Cell Physiol; 2022 Jul; 237(7):2729-2739. PubMed ID: 35342948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into N6-methyladenosine (m6A) modification of noncoding RNA in tumor microenvironment.
    Zhang Y; Zhan L; Li J; Jiang X; Yin L
    Aging (Albany NY); 2023 May; 15(9):3857-3889. PubMed ID: 37178254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
    Meijing Z; Tianhang L; Biao Y
    Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
    [No Abstract]   [Full Text] [Related]  

  • 14. An N6-methyladenosine regulation- and mRNAsi-related prognostic index reveals the distinct immune microenvironment and immunotherapy responses in lower-grade glioma.
    Tang G; Peng J; Huo L; Yin W
    BMC Bioinformatics; 2023 Jun; 24(1):225. PubMed ID: 37264314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research advances of N6-methyladenosine in diagnosis and therapy of pancreatic cancer.
    Chen S; Ren H; Zhang X; Chang L; Wang Z; Wu H; Zhang J; Ren J; Zhou L
    J Clin Lab Anal; 2022 Sep; 36(9):e24611. PubMed ID: 35837987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One Stone, Two Birds: N6-Methyladenosine RNA Modification in Leukemia Stem Cells and the Tumor Immune Microenvironment in Acute Myeloid Leukemia.
    Ouyang X; Gong Y
    Front Immunol; 2022; 13():912526. PubMed ID: 35720276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of N6-Methyladenosine Modification Patterns and Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
    Liu Y; Li G; Yang Y; Lu Z; Wang T; Wang X; Liu J
    Front Genet; 2021; 12():752025. PubMed ID: 35046996
    [No Abstract]   [Full Text] [Related]  

  • 18. N6-Methyladenosine Modification Participates in the Progression of Hepatitis B Virus-Related Liver Fibrosis by Regulating Immune Cell Infiltration.
    Zhao T; Qi J; Liu T; Wu H; Zhu Q
    Front Med (Lausanne); 2022; 9():821710. PubMed ID: 35308519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma.
    Shen S; Yan J; Zhang Y; Dong Z; Xing J; He Y
    Ann Transl Med; 2021 Jan; 9(1):59. PubMed ID: 33553352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. m6A Regulator-Associated Modification Patterns and Immune Infiltration of the Tumor Microenvironment in Hepatocarcinoma.
    Li J; Wang W; Zhou Y; Liu L; Zhang G; Guan K; Cui X; Liu X; Huang M; Cui G; Sun R
    Front Cell Dev Biol; 2021; 9():687756. PubMed ID: 34277630
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.